Novartis Vanrafia Phase III data support slowing of kidney function decline in patients with IgA nephropathy
Basel, February 13, 2026 – Novartis today announced final results from the…
ERA Congress: Long-term data show sustained efficacy and safety of zigakibart in patients with IgA nephropathy
VIENNA, June 5, 2025 /PRNewswire/ -- New 100-week data from the ongoing…
